Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Crinetics Pharmaceuticals Inc (NQ: CRNX ) 53.86 +0.71 (+1.34%) Streaming Delayed Price Updated: 12:55 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Crinetics Pharmaceuticals Inc < Previous 1 2 3 4 5 Next > Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 12, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals August 09, 2024 Via Benzinga CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 August 08, 2024 CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals June 28, 2024 Via Benzinga 17 Analysts Have This To Say About Crinetics Pharmaceuticals June 04, 2024 Via Benzinga 18 Analysts Have This To Say About Crinetics Pharmaceuticals May 14, 2024 Via Benzinga Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges August 08, 2024 ACRO/TRUTH Provides Authentic Patient Perspectives, Peer-Reviewed Data on Treatment-Related Symptoms, Side Effects and Quality-of-Life Impact of Current Acromegaly Standard-of-Care From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 July 18, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details July 14, 2024 10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session July 01, 2024 Via Benzinga 7 Biotech Stocks to Boost Your Portfolio to Peak Health June 26, 2024 With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. Via InvestorPlace EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner June 18, 2024 Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday June 04, 2024 Via Benzinga Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS) June 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly June 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs May 30, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday May 22, 2024 Via Benzinga Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts May 22, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. Via InvestorPlace Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 May 08, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 May 02, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 11, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why March 19, 2024 Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy & safety, with plans for FDA submission in 2024. Via Benzinga Exposures Product Safety Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Leading the Way in Tuesday Trading Based on Percentage Gain March 19, 2024 Via Investor Brand Network National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday March 19, 2024 U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 19, 2024 Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.